NCT00360672View on ClinicalTrials.gov

Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

Revlimid

25 mg/day, orally for 21 days with 7 days rest (28 day cycle).

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER